
Katalognummer: 870 - ABC-SC0081T
Produktkategori: Företag och industri > Vetenskap och laboratorium
Storlek: 1 vial
| Storage and shipping | Liquid Nitrogen |
|---|
ABC-SC0081T
CD34 is a glycosylated transmembrane protein and represents a well-known marker for primitive blood-and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial stem cells. CD34+ stem cells are multipotent and can differentiate to all hematopoietic cell types in blood. CD34+ cells can also give rise to all lymphohematopoietic lineages even though they comprise only a small percentage of the cell population. Our CD34+ cells are isolated using positive immunomagnetic cell separation procedures from single or mixed healthy donors. All cord blood is collected in Citric Phosphate with Dextrose Buffer (CPD) from fully consented IRB approved donors.
ABC-SC0082T
CD34 is a glycosylated transmembrane protein and represents a well-known marker for primitive blood-and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial stem cells. CD34+ stem cells are multipotent and can differentiate to all hematopoietic cell types in blood. CD34+ cells can also give rise to all lymphohematopoietic lineages even though they comprise only a small percentage of the cell population.Our CD34+ cells are isolated using positive immunomagnetic cell separation procedures from single or mixed healthy donors. All cord blood is collected in Citric Phosphate with Dextrose Buffer (CPD) from fully consented IRB approved donors.
ABC-SC0085T
Desired cells are isolated using positive magnetic isolation of CD34 from cord blood. CD34+ cells are targeted using uniform, superparamagnetic polymer beads coated with a primary monoclonal antibody specific for the CD34 membrane antigen predominantly expressed on human hematopoietic progenitor cells and endothelial progenitor cells. The isolated cells are poured off into a new tube, and are cryogenically preserved.
ABC-TC4280
CD133 (Prominin-1) is a glycoprotein with sub-cellular localization in plasma membrane protrusions. In humans, this protein was originally identified as an antigenic marker expressed on hematopoietic stem cells. In addition,CD133 is also expressed by neural and muscle progenitor cells. CD133+ cells are isolated in Gentaur's facilities from fresh cord blood. These cells are highly proliferative primitive progenitors. They can give rise to mature, terminally differentiated blood cells by means of directed differentiation. Gentaur also provides suitable expansion and differentiation media. Immediately after isolation, the freshly prepared CD133+ Progenitor Cells are cryopreserved using Gentaur's proprietary serum-free,animal component-free and defined freezing medium Cryo-SFM. Each cryo vial contains more than 100.000 viable cells after thawing.
ABC-SC0085
Human Lung Cancer Stem Cell; Frozen Vial and Plated cells are available. Cells are only guaranteed with purchase of Gentaur Media and Gentaur Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.
ABC-SC0105T
Cultures of dissociated NSCs were generated from human fetal brain tissue of 10-14 weeks gestation. NSCs were further cultured under low oxygen conditions and were transduced with retrovirus carrying L-MYC gene.HighlightsGenerated from dissociated NSCs from human fetal brain tissueDisplay both self-renewal and multipotent differentiation into neurons, oligodendrocytes, and astrocytesExpression of the L-MYC gene was confirmed by genomic PCR analysis (Li-Gutova-2016)Found to be non-tumorigenic in vivoFurther characterization shows: a normal, female karyotype, ability to differentiate into neuronal lineages, and demonstrated the lack of abnormal growth or tumorigenicity in vitro or in vivo.Pre-clinical studies indicate that neural stem cells (NSCs) can limit or reverse CNS damage through direct cell replacement, promotion of regeneration, or delivery of therapeutic agents. Immortalized NSC lines are in growing demand due to the inherent limitations of adult patient-derived NSCs, including availability, expandability, potential for genetic modifications, and costs.

By: Author , 2 Comment
3 mars 2026

By: Author , 2 Comment
30 januari 2026

By: Author , 2 Comment
23 augusti 2025

By: Author , 2 Comment
16 augusti 2025

